NEW YORK (GenomeWeb News) – Seegene and Selventa have entered into a collaborative agreement to develop molecular diagnostic products for "underserved markets" including autoimmune disease, cancer, and infectious diseases, the companies said today.

Under the partnership, the companies will combine Selventa's Systems Diagnostics "multi-omic analytics" platform with Seegene's qTOCE and DPO multiplex PCR chemistries to develop new molecular diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.